Spyre Therapeutics has commenced an underwritten public offering of its common stock to fund the advancement of its immunology pipeline. The clinical-stage biotechnology company intends to use net proceeds to support preclinical studies, clinical trials, and manufacturing efforts.

The offering is subject to market conditions, with no assurance regarding completion or final terms. Jefferies, TD Cowen, Leerink Partners, and Stifel are acting as joint book-running managers. LifeSci Capital serves as the passive bookrunner for the proposed transaction.

Use of Proceeds and Pipeline Advancement

Spyre plans to allocate funds to advance programs in Gastroenterology, Rheumatology, and Dermatology. A key component of the capital raise is funding a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Remaining proceeds will cover ongoing research, development, working capital, and general corporate purposes.

Offering Structure and Regulatory Status

The Company is expected to grant underwriters a 30-day option to purchase an additional 15% of shares offered. The registration statement on Form S-3 (File No. 333-297063) was filed with the Securities and Exchange Commission (SEC) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus.

What the Numbers Show

The decision to reserve a portion of proceeds specifically for SPY072's late-stage development signals a strategic pivot toward commercialization readiness. By securing capital now, Spyre aims to mitigate financing risks associated with Phase 3 trials, which typically require substantial upfront expenditure before revenue generation. The inclusion of a 15% over-allotment option provides flexibility for the company to capture additional capital if demand exceeds initial expectations.

Spyre Therapeutics approved equity inducement awards for two non-executive employees on October 1, 2026. The grants include 21,424 stock options and 6,604 restricted stock units (RSUs), material to the employees' acceptance of employment.

The Compensation Committee approved these awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. This action complies with Nasdaq Listing Rule 5635(c)(4), which permits such grants without shareholder approval when they are essential for hiring new personnel.

Award terms and vesting schedule

The stock options carry a 10-year term with an exercise price of $89.93, matching the closing share price on Nasdaq as of October 1, 2026. Vesting for the options follows a standard four-year structure: one-fourth vests on the first anniversary of the start date, with the remaining three-fourths vesting monthly in equal increments over the subsequent 36 months. Continuous service is required through each vesting date.

The RSUs follow a different vesting cadence tied to specific calendar dates. One-fourth of the RSUs vests on each of the next February 15, May 15, August 15, or November 15 occurring after the employee's start date. Like the options, RSU vesting is contingent upon continuous service.

Company profile

Spyre Therapeutics is a clinical-stage biotechnology company focused on immunology therapies. Its pipeline targets diseases by developing extended half-life antibodies against α4β7, TL1A, IL-23, and IL-17A/F, alongside rational combination programs aimed at improving disease control and treatment durability.